Nilutamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg
Reference Brands: Nilandron (USA), Nilandron (EU)
Category:
Oncology Cancer Care
Nilutamide is available in Tablets
and strengths such as 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nilutamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nilutamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nilutamide is a nonsteroidal antiandrogen used primarily in the treatment of prostate cancer, particularly in patients whose disease has spread to other parts of the body. It is commonly prescribed following surgical castration (orchiectomy) as part of combined androgen blockade therapy. Nilutamide is administered orally and works by binding to androgen receptors present on prostate cancer cells. By blocking these receptors, it prevents androgens such as testosterone from stimulating cancer cell growth, thereby helping to slow disease progression.
Nilutamide is marketed under the brand names Nilandron and Anandron and belongs to the class of antiandrogen therapies used in oncology. In addition to its approved use in prostate cancer, nilutamide has been studied for other hormonal conditions, including use in feminizing hormone therapy for transgender women and for the treatment of androgen-related skin conditions such as acne and seborrhea in women.
The medication plays an important role in managing advanced prostate cancer by targeting hormone-dependent tumor growth. Like other antiandrogens, nilutamide requires careful monitoring due to potential side effects, but it remains a valuable option in hormone-based cancer treatment strategies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing